Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma

Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27.

Authors

N Shah¹, P F Thall², P S Fox², Q Bashir¹, J J Shah³, S Parmar¹, P Lin⁴, P Kebriaei¹, Y Nieto¹, U R Popat¹, C M Hosing¹, A Cornelison¹, E J Shpall¹, R Z Orlowski³, R E Champlin¹, M H Qazilbash¹

Affiliations

¹ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Hematopatholoy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Hematopoietic Stem Cell Transplantation*
Humans
Lenalidomide
Melphalan / administration & dosage
Multiple Myeloma / mortality
Multiple Myeloma / therapy*
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives
Transplantation, Autologous
Treatment Outcome

Substances

Thalidomide
Lenalidomide
Melphalan

Grants and funding